The treatment options and prognoses of different subtypes of breast cancer vary (Gradishar et al., 2022); among these subtypes, the human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for nearly 15%–25% of all breast cancer cases and has a relatively poor prognosis (Orrantia-Borunda et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.